Hubei Jumpcan Pharmaceutical Co., Ltd.

SHSE:600566 Stock Report

Market Cap: CN¥32.7b

Hubei Jumpcan Pharmaceutical Future Growth

Future criteria checks 1/6

Hubei Jumpcan Pharmaceutical is forecast to grow earnings and revenue by 10% and 10.7% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 17.8% in 3 years.

Key information

10.0%

Earnings growth rate

9.6%

EPS growth rate

Pharmaceuticals earnings growth19.2%
Revenue growth rate10.7%
Future return on equity17.8%
Analyst coverage

Low

Last updated23 Aug 2023

Recent future growth updates

No updates

Recent updates

Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth

Mar 17
Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth

Earnings and Revenue Growth Forecasts

SHSE:600566 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202512,2893,108N/A3,7192
12/31/202411,0692,769N/A2,5822
12/31/202310,0382,489N/A3,1792
9/30/20239,6392,5233,1563,458N/A
6/30/20239,7622,4953,1043,354N/A
3/31/20239,2112,2662,7332,916N/A
12/31/20228,9962,1712,3772,621N/A
9/30/20228,1152,0392,0802,321N/A
6/30/20227,8111,8811,8992,135N/A
3/31/20227,8881,8611,8882,172N/A
12/31/20217,6311,7191,6461,894N/A
9/30/20217,2601,5901,6721,949N/A
6/30/20216,8961,4461,4851,827N/A
3/31/20216,0741,2521,4041,805N/A
12/31/20206,1651,2771,3521,782N/A
9/30/20205,8681,2771,3041,793N/A
6/30/20205,9841,3441,7242,228N/A
3/31/20206,8681,5771,7252,231N/A
12/31/20196,9401,6231,6012,148N/A
9/30/20197,0501,6851,4631,935N/A
6/30/20197,3111,8091,2511,787N/A
3/31/20197,1601,7311,2101,781N/A
12/31/20187,2081,6881,0411,709N/A
9/30/20186,9721,6259341,753N/A
6/30/20186,6361,4847011,500N/A
3/31/20186,3651,4005501,399N/A
12/31/20175,6421,2234431,189N/A
9/30/20175,3851,1655991,240N/A
6/30/20175,1341,076N/A1,161N/A
3/31/20174,9261,016N/A971N/A
12/31/20164,678934N/A913N/A
9/30/20164,458864N/A764N/A
6/30/20164,249796N/A779N/A
3/31/20164,020736N/A751N/A
12/31/20153,768687N/A645N/A
9/30/20153,585640N/A688N/A
6/30/20153,392595N/A662N/A
3/31/20153,178553N/A570N/A
12/31/20142,986519N/A616N/A
9/30/20142,829490N/A589N/A
6/30/20142,664461N/A329N/A
3/31/20142,524429N/A326N/A
12/31/20132,448403N/A287N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600566's forecast earnings growth (10% per year) is above the savings rate (2.9%).

Earnings vs Market: 600566's earnings (10% per year) are forecast to grow slower than the CN market (27% per year).

High Growth Earnings: 600566's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600566's revenue (10.7% per year) is forecast to grow slower than the CN market (15.2% per year).

High Growth Revenue: 600566's revenue (10.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600566's Return on Equity is forecast to be low in 3 years time (17.8%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.